Overview

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center
Treatments:
Hormones
Molybdenum
Tetrathiomolybdate